Edition:
United States

Summit Therapeutics PLC (SUMM.L)

SUMM.L on London Stock Exchange

177.50GBp
--
Change (% chg)

0.00 (+0.00%)
Prev Close
177.50
Open
177.50
Day's High
--
Day's Low
--
Volume
0
Avg. Vol
84,853
52-wk High
262.00
52-wk Low
88.00

Latest Key Developments (Source: Significant Developments)

Summit Therapeutics reports loss for year ended 31 January 2017 of 21.4 million pounds
Wednesday, 29 Mar 2017 07:00am EDT 

Summit Therapeutics Plc : Summit Therapeutics reports financial results for the fourth quarter and fiscal year ended 31 January 2017 and operational progress . Summit Therapeutics Plc - loss for year ended 31 January 2017 of 21.4 million pounds compared to a loss of 20.1 million pounds for year ended 31 January 2016 .Summit Therapeutics Plc - believes its existing cash and cash equivalents, including an anticipated $22.0 million payment for a near-term development milestone under licence and collaboration agreement with Sarepta, will be sufficient to enable it to fund its operating expenses and capital expenditure requirements through to 31 December 2018.  Full Article

Summit to extend ongoing trial of Ezutromid in patients with Duchenne disorder
Monday, 27 Mar 2017 07:00am EDT 

Summit Therapeutics Plc : Summit Therapeutics Plc - decision follows interim safety review by phaseout dmd's independent data monitoring committee . Summit to extend ongoing phaseout dmd clinical trial of Ezutromid in patients with dmd . Summit Therapeutics Plc - will proceed with planned extension phase of phaseout dmd . Summit Therapeutics Plc - now applied for regulatory approval to extend phaseout dmd from uk medicines, healthcare products regulatory agency, ethics committee . Summit Therapeutics Plc - in addition to extension phase of trial, regulatory submissions also include addition of a safety arm .Summit Therapeutics - safety arm to allow enrolment of patients from phase 1 clinical trials of ezutromid but didn't meet inclusion criteria for phaseout dmd.  Full Article

Summit enrols patients in the U.S. into a mid-stage trial of Ezutromid in patients with DMD
Wednesday, 16 Nov 2016 07:00am EST 

Summit Therapeutics Plc :Summit enrols patients in the United States into PhaseOut DMD, a phase 2 clinical trial of Ezutromid in patients with DMD.  Full Article

Summit's agreement with Sarepta also contains a standstill provision
Tuesday, 4 Oct 2016 07:05am EDT 

Summit Therapeutics Plc : Collaboration agreement with Sarepta also contains a standstill provision - SEC filing .Summit Therapeutics - Believes cash, cash equivalents, certain upfront payments from Sarepta collaboration to be sufficient to fund expenses through 2018.  Full Article

Sarepta and Summit enter into agreement for European rights to utrophin modulator pipeline
Tuesday, 4 Oct 2016 07:00am EDT 

Summit Therapeutics Plc : Summit receives $40 million upfront, with potential future ezutromid-related milestone payments totalling up to $522 million plus royalties . Sarepta also receives option for Latin American rights . As part of agreement, Sarepta also obtains an option to license latin american rights to Summit's utrophin modulator pipeline . If Sarepta elects to exercise option for Latin American rights, co would be entitled to additional fees, milestones and royalties . Sarepta and Summit to share research and development costs . Sarepta also receives option for Latin American rights . Sarepta Therapeutics and summit enter into exclusive license and collaboration agreement for european rights to summit’s utrophin modulator pipeline for the treatment of duchenne muscular dystrophy .Sarepta, co will share specified utrophin modulator-related research and development costs at a 45/55 pct split, respectively.  Full Article

Summit Therapeutics DMD treatment gets U.S. FDA fast track status
Monday, 26 Sep 2016 07:00am EDT 

Summit Therapeutics Plc :Receives fast track designation from U.S. FDA for Ezutromid in treatment of Duchenne muscular dystrophy.  Full Article

Summit receives fast track designation from FDA for Ezutromid
Monday, 26 Sep 2016 07:00am EDT 

Summit Therapeutics Plc :Summit receives fast track designation from U.S. FDA for Ezutromid in the treatment of duchenne muscular dystrophy.  Full Article

Summit reports positive phase 1 new formulation data for DMD Candidate Ezutromid
Tuesday, 9 Aug 2016 07:00am EDT 

Summit Therapeutics Plc : Summit reports positive phase 1 new formulation data and outlines route to market strategy for DMD Candidate Ezutromid .Initial F3 formulation 24-week biopsy data are now expected Q2/Q3 2017.  Full Article

First patient enrolled in Summit's PhaseOut DMD
Friday, 17 Jun 2016 07:00am EDT 

Summit Therapeutics : Anticipates reporting data periodically during trial with 24-week muscle biopsy data from first group of patients enrolled expected in jan 2017 .First patient enrolled in Summit's PhaseOut DMD, a phase 2 clinical trial of ezutromid in boys with DMD.  Full Article

Summit Therapeutics says Ridinilazole being prepared to enter Phase 3 trials
Thursday, 2 Jun 2016 07:00am EDT 

Summit Therapeutics : Summit Therapeutics reports financial results for the first quarter ended 30 April 2016 and operational progress . Loss for three months ended 30 April 2016 of £5.2 million compared to a loss of £3.4 million for three months ended 30 April 2015 . Summit Therapeutics Plc says cash and cash equivalents at 30 April 2016 of £10.0 million compared to £16.3 million at 31 January 2016 .Summit Therapeutics Plc says Ridinilazole being prepared to enter phase 3 clinical trials.  Full Article

More From Around the Web

BRIEF-Summit Therapeutics reports loss for year ended 31 January 2017 of 21.4 million pounds

* Summit Therapeutics reports financial results for the fourth quarter and fiscal year ended 31 January 2017 and operational progress